Circular RNAs hsa_circ_0000479 in peripheral blood mononuclear cells as novel biomarkers for systemic lupus erythematosus
Circular RNAs hsa_circ_0000479 in peripheral blood mononuclear cells as novel biomarkers for systemic lupus erythematosus
复制标题
外周血单核细胞中的环状RNA hsa_circ_0000479作为系统性红斑狼疮的新型生物标志物
DOI：
10.1080/08916934.2020.1728529
复制
发表时间：
2020-02-24
期刊：
影响因子：
3.5
通讯作者：
Li, Junming
中科院分区：
文献类型：
--
作者：
Luo, Qing;Lu, Zhang;Li, Junming
环状rna （circRNAs）是一类非编码rna，在系统性红斑狼疮（SLE）的诊断和预后中起着至关重要的作用。然而，来自不同报告的SLE中的circRNAs表达谱是不同的。在本研究中，11种circRNAs （hsa_circ_0000479、hsa_circ_0002316、hsa_circ_0000317、hsa_circ_0082688、hsa_circ_0082689、hsa_circ_0087798、hsa_circ_0008529、hsa_circ_0000787、hsa_circ_0021727、hsa_circ_0000175和hsa_circ_0003694）在我们先前研究中发现的SLE患者外周血单核细胞（PBMCs）和既往文献中发现的SLE患者T细胞中均显著上调。选择50例新发SLE患者、24例新发类风湿关节炎（RA）患者、24例新发强直性脊柱炎（AS）患者和45例年龄和性别匹配的健康对照（HC）的pbmc进行定量逆转录聚合酶链反应验证。结果证实，SLE患者的pbmc hsa_circ_0000479、hsa_circ_0082688和hsa_circ_0082689升高，而hsa_circ_0000175明显低于RA、AS和HC患者。对这些已证实的差异表达circRNAs的相关性分析显示，hsa_circ_0000479与C3水平和治疗相关，hsa_circ_0082688与抗dsdna水平相关，hsa_circ_0082689与抗dsdna水平、抗核小体频率和治疗相关。受试者工作特征曲线分析提示hsa_circ_0000479对SLE与AS、RA、HC的鉴别有显著价值（AUC = 0.825, p < 0.001）。此外，hsa_circ_0000479-anti-dsDNA联合模型能够有效区分SLE组和对照组（RA + AS + HC），灵敏度为86.00%(43/50)，特异性为100.00%(93/93)，准确率为95.10%（136/143）。本研究提示PBMC中的hsa_circ_0000479和hsa_circ_0000479-抗dsdna联合模型可能作为SLE诊断和疗效评价的潜在生物标志物。
Circular RNAs (circRNAs) are a class of non-coding RNAs that play a crucial role in diagnosis and prognosis of systemic lupus erythematosus (SLE). However, circRNAs expression profiling in SLE from different reports are different. In this study, 11 circRNAs (hsa_circ_0000479, hsa_circ_0002316, hsa_circ_0000317, hsa_circ_0082688, hsa_circ_0082689, hsa_circ_0087798, hsa_circ_0008529, hsa_circ_0000787, hsa_circ_0021727, hsa_circ_0000175, and hsa_circ_0003694) which were found to be significantly up-regulated in both peripheral blood mononuclear cells (PBMCs) from SLE patients in our previous study, and T cells from SLE patients in previous literature, were chosen for validation by quantitative reverse transcription-polymerase chain reaction in PBMCs from 50 new-onset SLE patients, 24 new-onset rheumatoid arthritis (RA) patients, 24 new-onset ankylosing spondylitis (AS) patients, and 45 age- and sex-matched healthy controls (HC). The results validated that PBMCs hsa_circ_0000479, hsa_circ_0082688, and hsa_circ_0082689 were increased, while hsa_circ_0000175 was significantly decreased in SLE patients than that in RA patients, AS patients, and HC. The correlation analysis of these confirmed differentially expressed circRNAs showed that hsa_circ_0000479 was associated with C3 level and treatment, hsa_circ_0082688 was associated with anti-dsDNA level, hsa_circ_0082689 was associated with anti-dsDNA level, anti-nuclesome frequency and treatment. Receiver operating characteristic curve anaylsis suggested that hsa_circ_0000479 has significant value in distinguishing SLE from AS patients, RA patients, and HC (AUC = 0.825, p < .001). Moreover, the hsa_circ_0000479-anti-dsDNA combination model could effectively discriminate the SLE group and the control groups (RA + AS + HC), with a sensitivity of 86.00% (43/50), a specificity of 100.00% (93/93), and an accuracy of 95.10% (136/143). This study suggested that hsa_circ_0000479 in PBMC and hsa_circ_0000479-anti-dsDNA combination model may serve as potential biomarkers for SLE diagnosis and evaluation of therapeutic effect.